Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:CNTA NASDAQ:COGT NASDAQ:RGC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$17.08+0.4%$20.60$16.92▼$48.45$1.59B-0.0511,209 shs5,911 shsCNTACentessa Pharmaceuticals$40.71+0.5%$39.72$12.74▼$40.56$6.27B1.112.21 million shs11.33 million shsCOGTCogent Biosciences$37.53+3.4%$34.42$7.03▼$43.73$6.20B0.342.53 million shs4.95 million shsRGCRegencell Bioscience$8.56-22.7%$24.06$8.55▼$69.00$5.48B1.65143,853 shs470,564 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International0.00%-0.06%-18.71%-19.94%-56.98%CNTACentessa Pharmaceuticals+0.52%+2.11%+2.42%+38.47%+186.69%COGTCogent Biosciences+3.36%+11.46%+14.88%+1.79%+418.37%RGCRegencell Bioscience-22.74%-42.24%-66.82%-66.30%-62.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$17.08+0.4%$20.60$16.92▼$48.45$1.59B-0.0511,209 shs5,911 shsCNTACentessa Pharmaceuticals$40.71+0.5%$39.72$12.74▼$40.56$6.27B1.112.21 million shs11.33 million shsCOGTCogent Biosciences$37.53+3.4%$34.42$7.03▼$43.73$6.20B0.342.53 million shs4.95 million shsRGCRegencell Bioscience$8.56-22.7%$24.06$8.55▼$69.00$5.48B1.65143,853 shs470,564 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International0.00%-0.06%-18.71%-19.94%-56.98%CNTACentessa Pharmaceuticals+0.52%+2.11%+2.42%+38.47%+186.69%COGTCogent Biosciences+3.36%+11.46%+14.88%+1.79%+418.37%RGCRegencell Bioscience-22.74%-42.24%-66.82%-66.30%-62.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.20Buy$46.43171.83% UpsideCNTACentessa Pharmaceuticals 2.21Hold$41.331.53% UpsideCOGTCogent Biosciences 2.86Moderate Buy$43.7316.51% UpsideRGCRegencell Bioscience 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest AAPG, CNTA, RGC, and COGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026AAPGAscentage Pharma Group International BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$48.006/10/2026AAPGAscentage Pharma Group International Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/10/2026AAPGAscentage Pharma Group International B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.005/29/2026COGTCogent Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$55.005/6/2026COGTCogent Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$55.004/24/2026AAPGAscentage Pharma Group International Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.004/20/2026CNTACentessa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CNTACentessa Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$35.00 ➝ $42.004/13/2026AAPGAscentage Pharma Group International BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$48.004/13/2026CNTACentessa Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$38.004/10/2026COGTCogent Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$82.10M19.43N/AN/A$2.04 per share8.37CNTACentessa Pharmaceuticals$15M419.94N/AN/A$3.92 per share10.39COGTCogent BiosciencesN/AN/AN/AN/A$3.84 per shareN/ARGCRegencell BioscienceN/AN/AN/AN/A$0.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$177.71MN/AN/AN/AN/AN/AN/AN/AN/ACNTACentessa Pharmaceuticals-$197.53M-$1.79N/AN/AN/AN/A-60.37%-44.17%8/11/2026 (Estimated)COGTCogent Biosciences-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%8/4/2026 (Estimated)RGCRegencell Bioscience-$3.58MN/AN/AN/AN/AN/AN/AN/AN/ALatest AAPG, CNTA, RGC, and COGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026RGCRegencell BioscienceN/A-$0.0050N/A-$0.0050N/AN/A5/5/2026Q1 2026CNTACentessa Pharmaceuticals-$0.38-$0.52-$0.14-$0.52N/AN/A5/5/2026Q1 2026COGTCogent Biosciences-$0.53-$0.53N/A-$0.53N/AN/A3/31/2026Q4 2025CNTACentessa Pharmaceuticals-$0.38-$0.48-$0.10-$0.48$0.77 millionN/A3/25/2026H2 2025AAPGAscentage Pharma Group InternationalN/A-$0.5150N/A-$0.5150N/A$24.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/ARGCRegencell BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International0.571.791.77CNTACentessa Pharmaceuticals0.239.539.53COGTCogent Biosciences0.4115.1415.14RGCRegencell BioscienceN/A1.41N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/ACNTACentessa Pharmaceuticals82.01%COGTCogent BiosciencesN/ARGCRegencell Bioscience0.13%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/ACNTACentessa Pharmaceuticals4.09%COGTCogent Biosciences6.59%RGCRegencell Bioscience2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60093.39 millionN/AN/ACNTACentessa Pharmaceuticals200154.73 million148.40 millionOptionableCOGTCogent Biosciences80170.87 million159.61 millionOptionableRGCRegencell Bioscience10494.49 million484.60 millionN/AAAPG, CNTA, RGC, and COGT HeadlinesRecent News About These CompaniesRegencell Bioscience (NASDAQ:RGC) Hits New 1-Year Low - Here's What Happened2 hours ago | americanbankingnews.comPomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limitedand Certain Officers – RGCJune 23 at 4:03 PM | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor HarmJune 23 at 1:00 PM | prnewswire.comRegencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their RightsJune 23 at 12:33 PM | businesswire.comPortnoy Law Firm Announces Class Action on Behalf of Regencell Bioscience Holdings Limited InvestorsJune 23 at 10:42 AM | globenewswire.comRGC Shareholder Alert: June 23, 2026 Lead Plaintiff Deadline in Regencell Bioscience Holdings Limited Securities Class Action - Contact The Gross Law FirmJune 23 at 10:00 AM | prnewswire.comRGC FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026June 23 at 9:22 AM | tmcnet.comRGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud LawsuitJune 23 at 5:08 AM | prnewswire.comDeadline Soon: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud LawsuitJune 22 at 7:06 PM | tmcnet.comREGENCELL DEADLINE JUNE 23rd: Bragar Eagel & Squire, P.C. Urgently Reminds Regencell Bioscience Holdings Limited Investors They Have Until June 23rd to Contact the Firm Seeking Lead Plaintiff RoleJune 22 at 5:16 PM | globenewswire.comDeadline Soon: Regencell Bioscience Holdings Limited (RGC)Â Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud LawsuitJune 22 at 1:11 PM | businesswire.comDEADLINE ALERT for LKQ, RGC, and GLOB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersJune 22 at 10:53 AM | globenewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 23, 2026 in Regencell Bioscience Holdings Limited Lawsuit - RGCJune 22 at 10:17 AM | globenewswire.comREGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited ...June 21, 2026 | gazettextra.comGREGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action – RGCJune 21, 2026 | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor HarmJune 21, 2026 | globenewswire.comRGC DEADLINE: The Gross Law Firm Reminds Regencell Bioscience Holdings Limited Investors of Upcoming Securities Class Action DeadlineJune 19, 2026 | globenewswire.comRelevant Gold Announces Results of Annual and Special General Meeting and Welcomes New Board MemberJune 18, 2026 | accessnewswire.comAREGENCELL DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action – RGCJune 18, 2026 | globenewswire.comSueWallSt Reminds Regencell Bioscience Holdings Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 23, 2026 - RGCJune 18, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAAPG, CNTA, RGC, and COGT Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$17.08 +0.07 (+0.41%) Closing price 06/24/2026 03:54 PM EasternExtended Trading$17.14 +0.07 (+0.38%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Centessa Pharmaceuticals NASDAQ:CNTA$40.71 +0.21 (+0.52%) Closing price 06/23/2026 07:33 PM EasternExtended Trading$40.71 0.00 (0.00%) As of 06/23/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Cogent Biosciences NASDAQ:COGT$37.53 +1.22 (+3.36%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$37.50 -0.03 (-0.08%) As of 06:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Regencell Bioscience NASDAQ:RGC$8.56 -2.52 (-22.74%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$9.17 +0.61 (+7.14%) As of 06:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
